Skip to main content

Table 1 KRAS genotype frequencies in the study population

From: KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

Study population

Genotype

Frequency

N %

OR (95% CI)

p value

Controls

wild (TT)

221/269 (82.2)

1.0

 
 

variable (TG/GG)

48/269 (17.8)

  

Sporadic cases

wild (TT)

434/524 (82.8)

0.96 (0.65-1.40)

0.814

 

variable (TG/GG)

90/524 (17.2)

  

Familial cases

wild (TT)

135/165 (81.8)

1.02 (0.62-1.69)

0.929

 

variable (TG/GG)

30/165 (18.2)

  

BRCA carriers

wild (TT)

26/29 (89.7)

0.53 (0.15-1.83)

0.316

 

variable (TG/GG)

3/29 (10.3)

  

BRCA1 carriers

wild (TT)

18/20 (90.0)

0.51 (0.12-2.28)

0.379

 

variable (TG/GG)

2/20 (10.0)

  

BRCA2 carriers

wild (TT)

8/9 (88.9)

0.58 (0.07-4.71)

0.606

 

variable (TG/GG)

1/9 (11.1)

  

Non-BRCA carriers

wild (TT)

109/136 (80.1)

1.14 (0.68-1.93)

0.623

 

variable (TG/GG)

27/136 (19.9)

 Â